SECsense Logo

AstraZeneca PLC's 2024 Financial Report: Key Insights & AGM Details

$AZN
Form 6-K
Filed on: 2025-02-18
Source
AstraZeneca PLC's 2024 Financial Report: Key Insights & AGM Details

Based on the provided financial report section for AstraZeneca PLC, here are the key insights and information extracted:

  1. Document Type: This is a Form 6-K, which is typically used by foreign companies to provide information to the SEC.
  2. Report Date: The financial report is dated February 18, 2025.
  3. Company Information:
  • Name: AstraZeneca PLC
  • Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
  1. Commission File Number: 001-11960.
  2. Reporting Framework: The report confirms that AstraZeneca is filing under Form 20-F.
  3. Access to the Annual Report:
  • The Annual Financial Report and Form 20-F Information for the year 2024 is announced and will be available for inspection at the National Storage Mechanism website.
  • The report can also be accessed on the company’s website: www.astrazeneca.com.
  1. Shareholder Communication: The Annual Report will be dispatched to shareholders soon, and the Annual General Meeting (AGM) is scheduled for April 11, 2025. Relevant documents for the AGM will be published and distributed to shareholders.
  2. Explanatory Note: The report includes regulated information such as:
  • Principal risks and uncertainties facing the company.
  • Directors' responsibility statement regarding the Financial Statements and Directors' Report.
  • A statement on related party transactions.
  1. Company Overview: AstraZeneca is identified as a global biopharmaceutical company focusing on prescription medicines in various therapeutic areas, including Oncology and Rare Diseases. It operates in over 125 countries.
  2. Contact Information: The Company Secretary is Adrian Kemp, who is the authorized signatory for the report.
  3. Signature: Signed by Adrian Kemp on behalf of AstraZeneca PLC.

Overall, the report serves to inform stakeholders about AstraZeneca's financial performance and governance, while also ensuring compliance with regulatory requirements. The upcoming AGM and the availability of the Annual Report are crucial for shareholder engagement and transparency.